Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
Incyte Corporation
Eli Lilly and Company
BioNTech SE
Hoffmann-La Roche
EMD Serono
NuCana plc
University of Michigan Rogel Cancer Center
Abramson Cancer Center at Penn Medicine
Johannes Gutenberg University Mainz
University of Miami
Massachusetts General Hospital
University of Michigan Rogel Cancer Center
Sanofi
University of Rochester
Columbia University
AstraZeneca
Eli Lilly and Company